Filgrastim biosimilar - Mycenax Biotech
Alternative Names: GranNEXLatest Information Update: 12 Nov 2021
At a glance
- Originator Mycenax Biotech
 - Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
 - Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 
Highest Development Phases
- No development reported Neutropenia
 
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Neutropenia in Taiwan (SC)
 - 09 Sep 2019 Filgrastim biosimilar is still in preclinical trials for Neutropenia in Taiwan (Mycenax Biotech pipeline, September 2019)
 - 28 Aug 2019 No recent reports of development identified for preclinical development in Neutropenia in Taiwan (SC)